Sorafenib Dose Escalation Not Supported in Most Untreated RCC Patients

Although the use of sorafenib in patients with treatment-naive metastatic renal cell carcinoma demonstrated clinical benefit, a phase IIb study did not support the use of dose escalation in these patients.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Tags: Genitourinary Cancers Kidney Cancer News Renal Cell Carcinoma Source Type: news